{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T15:11:16Z","timestamp":1791472276140,"version":"4.3.4"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,8,22]],"date-time":"2022-08-22T00:00:00Z","timestamp":1661126400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,8,22]],"date-time":"2022-08-22T00:00:00Z","timestamp":1661126400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1007\/s00262-022-03281-7","type":"journal-article","created":{"date-parts":[[2022,8,22]],"date-time":"2022-08-22T11:02:24Z","timestamp":1661166144000},"page":"591-598","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Risk of pneumonitis in non-small cell lung cancer patients with preexisting interstitial lung diseases treated with immune checkpoint inhibitors: a nationwide retrospective cohort study"],"prefix":"10.1007","volume":"72","author":[{"given":"Kenji","family":"Sawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Izumi","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7477-4071","authenticated-orcid":false,"given":"Koji","family":"Kawakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,22]]},"reference":[{"issue":"3","key":"3281_CR1","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1016\/j.athoracsur.2015.03.094","volume":"100","author":"T Omori","year":"2015","unstructured":"Omori T, Tajiri M, Baba T, Ogura T, Iwasawa T, Okudela K et al (2015) Pulmonary resection for lung cancer in patients with idiopathic interstitial pneumonia. Ann Thorac Surg 100(3):954\u2013960. https:\/\/doi.org\/10.1016\/j.athoracsur.2015.03.094","journal-title":"Ann Thorac Surg"},{"key":"3281_CR2","doi-asserted-by":"publisher","unstructured":"Sato T, Teramukai S, Kondo H, Watanabe A, Ebina M, Kishi K et al (2014) Impact and predictors of acute exacerbation of interstitial lung diseases after pulmonary resection for lung cancer. J Thorac Cardiovasc Surg 147(5):1604\u201311 e3. https:\/\/doi.org\/10.1016\/j.jtcvs.2013.09.050","DOI":"10.1016\/j.jtcvs.2013.09.050"},{"issue":"7","key":"3281_CR3","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1097\/JTO.0b013e318216ee6b","volume":"6","author":"H Kenmotsu","year":"2011","unstructured":"Kenmotsu H, Naito T, Kimura M, Ono A, Shukuya T, Nakamura Y et al (2011) The risk of cytotoxic chemotherapy-related exacerbation of interstitial lung disease with lung cancer. J Thorac Oncol 6(7):1242\u20131246. https:\/\/doi.org\/10.1097\/JTO.0b013e318216ee6b","journal-title":"J Thorac Oncol"},{"issue":"3","key":"3281_CR4","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s00280-014-2670-y","volume":"75","author":"H Kenmotsu","year":"2015","unstructured":"Kenmotsu H, Naito T, Mori K, Ko R, Ono A, Wakuda K et al (2015) Effect of platinum-based chemotherapy for non-small cell lung cancer patients with interstitial lung disease. Cancer Chemother Pharmacol 75(3):521\u2013526. https:\/\/doi.org\/10.1007\/s00280-014-2670-y","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"3281_CR5","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.lungcan.2010.04.014","volume":"71","author":"Y Minegishi","year":"2011","unstructured":"Minegishi Y, Sudoh J, Kuribayasi H, Mizutani H, Seike M, Azuma A et al (2011) The safety and efficacy of weekly paclitaxel in combination with carboplatin for advanced non-small cell lung cancer with idiopathic interstitial pneumonias. Lung Cancer 71(1):70\u201374. https:\/\/doi.org\/10.1016\/j.lungcan.2010.04.014","journal-title":"Lung Cancer"},{"issue":"2","key":"3281_CR6","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1007\/s10147-013-0554-5","volume":"19","author":"N Watanabe","year":"2014","unstructured":"Watanabe N, Taniguchi H, Kondoh Y, Kimura T, Kataoka K, Nishiyama O et al (2014) Chemotherapy for extensive-stage small-cell lung cancer with idiopathic pulmonary fibrosis. Int J Clin Oncol 19(2):260\u2013265. https:\/\/doi.org\/10.1007\/s10147-013-0554-5","journal-title":"Int J Clin Oncol"},{"issue":"6","key":"3281_CR7","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1016\/j.chest.2018.08.1048","volume":"154","author":"K Suresh","year":"2018","unstructured":"Suresh K, Naidoo J, Lin CT, Danoff S (2018) Immune checkpoint immunotherapy for non-small cell lung cancer: benefits and pulmonary toxicities. Chest 154(6):1416\u20131423. https:\/\/doi.org\/10.1016\/j.chest.2018.08.1048","journal-title":"Chest"},{"issue":"12","key":"3281_CR8","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","volume":"4","author":"DY Wang","year":"2018","unstructured":"Wang DY, Salem JE, Cohen JV, Chandra S, Menzer C, Ye F et al (2018) Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol 4(12):1721\u20131728. https:\/\/doi.org\/10.1001\/jamaoncol.2018.3923","journal-title":"JAMA Oncol"},{"issue":"1","key":"3281_CR9","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s00262-019-02431-8","volume":"69","author":"R Shibaki","year":"2020","unstructured":"Shibaki R, Murakami S, Matsumoto Y, Yoshida T, Goto Y, Kanda S et al (2020) Association of immune-related pneumonitis with the presence of preexisting interstitial lung disease in patients with non-small lung cancer receiving anti-programmed cell death 1 antibody. Cancer Immunol Immunother 69(1):15\u201322. https:\/\/doi.org\/10.1007\/s00262-019-02431-8","journal-title":"Cancer Immunol Immunother"},{"issue":"2","key":"3281_CR10","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1111\/1759-7714.13736","volume":"12","author":"T Isono","year":"2021","unstructured":"Isono T, Kagiyama N, Takano K, Hosoda C, Nishida T, Kawate E et al (2021) Outcome and risk factor of immune-related adverse events and pneumonitis in patients with advanced or postoperative recurrent non-small cell lung cancer treated with immune checkpoint inhibitors. Thorac Cancer 12(2):153\u2013164. https:\/\/doi.org\/10.1111\/1759-7714.13736","journal-title":"Thorac Cancer"},{"issue":"12","key":"3281_CR11","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1164\/rccm.200710-1501OC","volume":"177","author":"S Kudoh","year":"2008","unstructured":"Kudoh S, Kato H, Nishiwaki Y, Fukuoka M, Nakata K, Ichinose Y et al (2008) Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study. Am J Respir Crit Care Med 177(12):1348\u20131357. https:\/\/doi.org\/10.1164\/rccm.200710-1501OC","journal-title":"Am J Respir Crit Care Med"},{"issue":"8","key":"3281_CR12","doi-asserted-by":"publisher","first-page":"4115","DOI":"10.1002\/cam4.1579","volume":"7","author":"P Cui","year":"2018","unstructured":"Cui P, Liu Z, Wang G, Ma J, Qian Y, Zhang F et al (2018) Risk factors for pneumonitis in patients treated with anti-programmed death-1 therapy: a case-control study. Cancer Med 7(8):4115\u20134120. https:\/\/doi.org\/10.1002\/cam4.1579","journal-title":"Cancer Med"},{"issue":"7","key":"3281_CR13","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1200\/JCO.2016.68.2005","volume":"35","author":"J Naidoo","year":"2017","unstructured":"Naidoo J, Wang X, Woo KM, Iyriboz T, Halpenny D, Cunningham J et al (2017) Pneumonitis in patients treated with anti-programmed death-1\/Programmed Death Ligand 1 Therapy. J Clin Oncol 35(7):709\u2013717. https:\/\/doi.org\/10.1200\/JCO.2016.68.2005","journal-title":"J Clin Oncol"},{"issue":"5","key":"3281_CR14","doi-asserted-by":"publisher","first-page":"2664","DOI":"10.1002\/cam4.2104","volume":"8","author":"Y Huang","year":"2019","unstructured":"Huang Y, Fan H, Li N, Du J (2019) Risk of immune-related pneumonitis for PD1\/PD-L1 inhibitors: systematic review and network meta-analysis. Cancer Med 8(5):2664\u20132674. https:\/\/doi.org\/10.1002\/cam4.2104","journal-title":"Cancer Med"},{"issue":"2","key":"3281_CR15","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/S1470-2045(20)30641-0","volume":"22","author":"L Paz-Ares","year":"2021","unstructured":"Paz-Ares L, Ciuleanu TE, Cobo M, Schenker M, Zurawski B, Menezes J et al (2021) First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. Lancet Oncol 22(2):198\u2013211. https:\/\/doi.org\/10.1016\/S1470-2045(20)30641-0","journal-title":"Lancet Oncol"},{"key":"3281_CR16","doi-asserted-by":"publisher","unstructured":"Nakashima M, Takeuchi M, Kawakami K (2020) Effectiveness and safety of Regorafenib vs. Trifluridine\/Tipiracil in unresectable colorectal cancer: a retrospective cohort study. Clin Colorectal Cancer 19(4):e208\u2013e25. https:\/\/doi.org\/10.1016\/j.clcc.2020.05.003","DOI":"10.1016\/j.clcc.2020.05.003"},{"issue":"3","key":"3281_CR17","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1002\/pds.4703","volume":"28","author":"S Yamada","year":"2019","unstructured":"Yamada S, Sato I, Kawakami K (2019) A descriptive epidemiological study on the treatment options for head and neck cancer: transition before and after approval of cetuximab. Pharmacoepidemiol Drug Saf 28(3):330\u2013336. https:\/\/doi.org\/10.1002\/pds.4703","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"3281_CR18","unstructured":"Medical.data.Vision Co., Ltd. Press release. [Available from: https:\/\/www.mdv.co.jp\/press\/2020\/detail_1471.html."},{"issue":"4","key":"3281_CR19","first-page":"279","volume":"55","author":"M Ishii","year":"2012","unstructured":"Ishii M (2012) DRG\/PPS and DPC\/PDPS as prospective payment systems. Japan Med Assoc J 55(4):279\u2013291","journal-title":"Japan Med Assoc J"},{"key":"3281_CR20","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s40780-015-0016-5","volume":"1","author":"S Tanaka","year":"2015","unstructured":"Tanaka S, Seto K, Kawakami K (2015) Pharmacoepidemiology in Japan: medical databases and research achievements. J Pharm Health Care Sci 1:16. https:\/\/doi.org\/10.1186\/s40780-015-0016-5","journal-title":"J Pharm Health Care Sci"},{"issue":"11","key":"3281_CR21","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/0895-4356(94)90129-5","volume":"47","author":"M Charlson","year":"1994","unstructured":"Charlson M, Szatrowski TP, Peterson J, Gold J (1994) Validation of a combined comorbidity index. J Clin Epidemiol 47(11):1245\u20131251. https:\/\/doi.org\/10.1016\/0895-4356(94)90129-5","journal-title":"J Clin Epidemiol"},{"key":"3281_CR22","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.lungcan.2018.09.015","volume":"125","author":"JY Cho","year":"2018","unstructured":"Cho JY, Kim J, Lee JS, Kim YJ, Kim SH, Lee YJ et al (2018) Characteristics, incidence, and risk factors of immune checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer. Lung Cancer 125:150\u2013156. https:\/\/doi.org\/10.1016\/j.lungcan.2018.09.015","journal-title":"Lung Cancer"},{"key":"3281_CR23","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.lungcan.2018.10.001","volume":"125","author":"T Yamaguchi","year":"2018","unstructured":"Yamaguchi T, Shimizu J, Hasegawa T, Horio Y, Inaba Y, Yatabe Y et al (2018) Pre-existing pulmonary fibrosis is a risk factor for anti-PD-1-related pneumonitis in patients with non-small cell lung cancer: a retrospective analysis. Lung Cancer 125:212\u2013217. https:\/\/doi.org\/10.1016\/j.lungcan.2018.10.001","journal-title":"Lung Cancer"},{"key":"3281_CR24","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.ejca.2020.03.017","volume":"132","author":"D Maillet","year":"2020","unstructured":"Maillet D, Corbaux P, Stelmes JJ, Dalle S, Locatelli-Sanchez M, Perier-Muzet M et al (2020) Association between immune-related adverse events and long-term survival outcomes in patients treated with immune checkpoint inhibitors. Eur J Cancer 132:61\u201370. https:\/\/doi.org\/10.1016\/j.ejca.2020.03.017","journal-title":"Eur J Cancer"},{"issue":"4","key":"3281_CR25","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1378\/chest.12-0803","volume":"143","author":"V Navaratnam","year":"2013","unstructured":"Navaratnam V, Fogarty AW, Glendening R, McKeever T, Hubbard RB (2013) The increasing secondary care burden of idiopathic pulmonary fibrosis: hospital admission trends in England from 1998 to 2010. Chest 143(4):1078\u20131084. https:\/\/doi.org\/10.1378\/chest.12-0803","journal-title":"Chest"},{"issue":"2","key":"3281_CR26","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","volume":"378","author":"MA Postow","year":"2018","unstructured":"Postow MA, Sidlow R, Hellmann MD (2018) Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med 378(2):158\u2013168. https:\/\/doi.org\/10.1056\/NEJMra1703481","journal-title":"N Engl J Med"},{"issue":"17","key":"3281_CR27","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","volume":"36","author":"JR Brahmer","year":"2018","unstructured":"Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM et al (2018) Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 36(17):1714\u20131768. https:\/\/doi.org\/10.1200\/JCO.2017.77.6385","journal-title":"J Clin Oncol"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-022-03281-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-022-03281-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-022-03281-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,23]],"date-time":"2023-02-23T06:29:30Z","timestamp":1677133770000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-022-03281-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,22]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["3281"],"URL":"https:\/\/doi.org\/10.1007\/s00262-022-03281-7","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,22]]},"assertion":[{"value":"20 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"K. Sawa receives payment for lectures from Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., and Nippon Boehringer Ingelheim Co., Ltd. I. Sato holds stack in Astellas Pharma Inc. and Daiichi Sankyo Co., Ltd.M. Takeuchi received a consultation fee from Eisai Co., Ltd. K. Kawakami received advisory fees from Shin Nippon Biomedical Laboratories, Ltd., JMDC Inc., Leber Inc. Kaken Pharmaceutical Co.,Ltd., and Advanced Medical Care Inc.; payment for lectures including service on speakers bureaus from Mitsubishi Corp., Mitsubishi Chemical Holdings Corp., Daiichi Sankyo Co., Ltd., Chugai Pharmaceutical Co., Ltd., Kyoto University Original Co., Ltd., McKinsey & Co. Inc., Nikkei Business Publications, Inc., Astellas Pharma Inc., AstraZeneca K.K., Mitsubishi Tanabe Pharma Corp., and IQVIA Services Japan K.K.; research funds from Sumitomo Dainippon Pharma Co., Ltd., Pfizer Inc., Stella Pharma Corporation, CMIC Co., Ltd., Suntory Beverage & Food Ltd., Eisai Co., Ltd., Kyowa Kirin Co., Ltd., Mitsubishi Corp. Ltd. and Real World Data, Co., Ltd.; and holds stock in Real World Data, Co., Ltd.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}